Novel intravesical bacterial immunotherapy induces rejection of BCG-unresponsive established bladder tumors
ntravesical BCG is the gold-standard therapy for non-muscle invasive bladder cancer (NMIBC)
Identification of sSIGLEC5 and sLAG3 as New Relapse Predictors in Lung Cancer
Lung cancer (LC) continues to be the leading cause of cancer-related deaths in both men and women worldwide.
Dectin-1 Signaling Update: New Perspectives for Trained Immunity
The C-type lectin receptor Dectin-1 was originally described as the β-glucan receptor expressed in myeloid cells, with crucial functions in antifungal responses.
Cellular and humoral functional responses after BNT162b2 mRNA vaccination differ longitudinally between naive and subjects recovered from COVID-19
We have analyzed BNT162b2 vaccine-induced immune responses in naive subjects and individuals recovered from coronavirus disease 2019 (COVID-19), both soon after (14 days) and later after (almost 8 months) vaccination.
The Bacterial Mucosal Immunotherapy MV130 Protects Against SARS-CoV-2 Infection and Improves COVID-19 Vaccines Immunogenicity
COVID-19-specific vaccines are efficient prophylactic weapons against SARS-CoV-2 virus.
SARS-CoV-2 IgG seropositivity in a cohort of 449 non-hospitalized individuals during Spanish COVID-19 lockdown
The Coronavirus Disease of 2019 (COVID-19) pandemic caused by SARS-CoV-2 led the Spanish government to impose a national lockdown in an attempt to control the spread of the infection.
Soluble SIGLEC5: A New Prognosis Marker in Colorectal Cancer Patients
Colorectal cancer (CRC) is the second most deadly and third most commonly diagnosed cancer worldwide.
DNGR-1 limits Flt3L-mediated antitumor immunity by restraining tumor-infiltrating type I conventional dendritic cells
Conventional type 1 dendritic cells (cDC1s) are central to antitumor immunity and their presence in the tumor microenvironment associates with improved outcomes in patients with cancer.